Marché du traitement par thérapie cellulaire MEA CAR-T – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et taille du marché du traitement par thérapie cellulaire MEA CAR-T     

La prévalence croissante du cancer dans la région MEA est un facteur clé pour le marché de la thérapie cellulaire Car-T, créant un besoin croissant de traitements plus efficaces. Cependant, le coût élevé de la thérapie cellulaire Car-T constitue un obstacle important, limitant potentiellement son accessibilité. Le côté positif est qu'il existe une opportunité de croissance du marché grâce à l'accent croissant mis par la région sur le développement des infrastructures de santé et le tourisme médical, en particulier dans des pays comme Singapour. Néanmoins, l'un des principaux défis est la nécessité de mener des recherches et des essais cliniques approfondis pour établir l'efficacité et la sécurité à long terme de la thérapie cellulaire Car-T dans cette région.    

Data Bridge Market Research analyse que le marché du traitement par thérapie cellulaire MEA CAR-T devrait atteindre 105,69 millions USD d'ici 2031, avec un TCAC de 30,7 % au cours de la période de prévision de 2027 à 2031.    

Market Definition

CAR-T cell therapy or chimeric antigen receptor T cells are those T cells which are genetically engineered in order to produce an artificial T-cell receptor which can be used as an immunotherapy for the treatment of various cancers. Chimeric antigen receptors are those receptor proteins that have been engineered in the laboratories to provide the T-cells with the novel ability to target a specific protein. These receptors are chimeric because they are combined with both antigen-binding and T-cell activating functions into a single receptor. Once the CAR-T cells infused in the patient’s body then they act as a “living cell” which has the ability or designed in such a way that they can kill the harmful cancer cells without affecting the healthy cells. The CAR-T cells when comes in contact with the targeted antigen on a cell, CAR-T cells binds with it and becomes activated and multiply to become cytotoxic.

MEA CAR-T Cell Therapy Treatment Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Increasing Prevalence of Cancer and other Target Diseases      

Cancer is a leading cause of morbidity and mortality worldwide, and the incidence of cancer is rising in these regions due to factors such as population growth, aging, and lifestyle changes. Additionally, there is a growing burden of other target diseases, such as hematological disorders, which can also be treated with CAR-T cell therapy. This increasing disease burden underscores the need for innovative and effective treatments like CAR-T cell therapy, driving market growth.

• Growing Awareness and Acceptance of Car-T Cell Therapy

The growing awareness and acceptance of CAR-T cell therapy as an effective treatment in the MEA, Saudi Arabia, and MEA regions are driven by various factors. These include heightened media coverage, educational efforts by healthcare organizations, and the sharing of success stories that highlight the therapy's effectiveness. Consequently, patients and healthcare providers are gaining a better understanding of CAR-T cell therapy's potential advantages, such as higher response rates and long-lasting remissions, especially in cases that are refractory or have relapsed. Additionally, regulatory approvals and endorsements in these regions have cemented CAR-T cell therapy's status as a legitimate and viable treatment option.

Opportunity

• The Extensive Pipeline of Car-T Cell Therapy

The extensive pipeline represents a wealth of opportunities for patients, healthcare providers, and the healthcare industry as a whole. This pipeline includes a range of CAR-T cell therapy products in various stages of development, from early preclinical Research to advanced clinical trials. The pipeline reflects ongoing innovation and investment in CAR-T cell therapy, with new products being developed to target different types of cancer and hematological disorders. Additionally, the pipeline includes products aimed at improving the safety, efficacy, and accessibility of CAR-T cell therapy, such as next-generation CAR-T cell therapies and off-the-shelf CAR-T cell products.

Restraints/Challenges

• High Cost of Car-T Cell Therapy

CAR-T cell therapy is a highly personalized and complex treatment that involves modifying a patient's immune cells to target cancer cells, making it a costly procedure. Factors contributing to this high cost include the specialized manufacturing process, extensive clinical monitoring, and infrastructure requirements. As a result, many patients, particularly those without adequate insurance coverage or financial resources, face challenges accessing this innovative therapy. The cost of clinical trials, regulatory compliance, and post-treatment monitoring further increases the overall expense, highlighting the financial burden for patients, especially those from lower-income backgrounds.

• Potential Risks and Adverse Effects of Treatment

CAR-T cell therapy, despite its promising efficacy, presents potential risks and side effects that pose challenges for patients and healthcare providers in the MEA, Saudi Arabia, and MEA regions. The most common side effects include cytokine release syndrome (CRS) and neurotoxicity. CRS, a significant adverse effect, occurs when infused CAR T cells recognize and attack cancer cells, leading to the release of cytokines like interleukin-6 (IL-6). This immune response causes systemic inflammation, manifesting in symptoms from mild fever and flu-like symptoms to potentially life-threatening complications like hypotension, respiratory distress, and multiorgan failure. CAR T-cell therapy can also trigger immune effector cell-associated neurotoxicity syndrome (ICANS), characterized by neurological symptoms such as confusion, seizures, and impaired speech. These side effects result from immune system overactivation and cytokine release, emphasizing the need for vigilant monitoring and prompt management to ensure patient safety and treatment efficacy.

Recent Developments

• In December 2023, Gilead Sciences, Inc. announced U.S. FDA has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy
• In May 2022, Bristol-Myers Squibb Company announced the approval of Opdivo plus Yervoy as a first line treatment for adult patients by Japan's Ministry of Health, Labour and Welfare. This may help the company to strengthen its product portfolio
• In February 2022, the FDA has approved CARVYKTI™ (ciltacabtagene autoleucel) from Janssen for treating adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, marking Janssen's inaugural cell therapy. This will underscore the dedication to advance their oncology treatment options
• In December 2021, Novartis AG has signed an agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), enhancing the company's immuno-oncology Research and development. This collaboration contributes to Novartis Oncology's broader initiative to advance innovation in cancer treatments by incorporating a potentially transformative therapy into its expanding immunotherapy platform

MEA CAR-T Cell Therapy Treatment Market Scope   

The MEA CAR-T cell therapy treatment market is segmented into seven notable segments based on product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Product

• Autologous CAR-T Cells
• Allogeneic CAR-T Cells

On the basis of product, the market is segmented into autologous CAR-T cells and allogeneic CAR-T cells.

Structure

• First Generation CAR-T Cells
• Second Generation CAR-T Cells
• Third Generation CAR-T Cells
• Fourth Generation CAR-T Cells 

On the basis of structure, the market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells, and fourth generation CAR-T cells.

Targeted Antigens

• Antigens on Solid Tumors
• Antigens on Hematologic Malignancies
• Others  

On the basis of targeted antigens, the market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. 

Brand

• Yescarta
• Kymriah
• Tecartus
• Others 

On the basis of brand, the market is segmented into yescarta, kymriah, tecartus and others.

Therapeutic Application

• Hematological Malignancies
• Pancreatic Cancer
• Breast Cancer
• Lung Cancer
• Gastric Cancer
• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Diffuse Large B-Cell Lymphoma
• Acute Lymphoblastic Leukemia (ALL)
• Others      

Sur la base de l'application thérapeutique, le marché est segmenté en lymphome diffus à grandes cellules B, lymphome folliculaire, leucémie aiguë lymphoblastique (LAL), lymphome à cellules du manteau, myélome multiple, hémopathies malignes, cancer du poumon, leucémie lymphoïde chronique, cancer gastrique, cancer du pancréas, cancer du sein et autres.   

Utilisateur final

• Hôpitaux
• Cliniques spécialisées
• Autres

Sur la base de l’utilisateur final, le marché est segmenté en hôpitaux, cliniques spécialisées et autres. 

Canal de distribution

• Hôpitaux Pharmacie
• Autres

Sur la base du canal de distribution, le marché est segmenté en hôpitaux, pharmacies et autres.

Analyse/perspectives régionales du marché du traitement par thérapie cellulaire MEA CAR-T

Le marché du traitement par thérapie cellulaire MEA CAR-T est segmenté en sept segments notables basés sur le produit, la structure, les antigènes ciblés, la marque, l'application thérapeutique, l'utilisateur final et le canal de distribution.

Les pays couverts dans ce rapport de marché sont l’Arabie saoudite, l’Afrique du Sud, les Émirats arabes unis, Israël, le Koweït, l’Égypte et le reste du Moyen-Orient et de l’Afrique.

L'Arabie saoudite devrait dominer le marché du traitement par thérapie cellulaire MEA CAR-T en raison de son infrastructure de soins de santé avancée, du soutien gouvernemental, du secteur du tourisme médical en pleine croissance, des activités de recherche et développement et de la demande croissante de traitements avancés.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs douaniers d'import-export sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques régionales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché du traitement par thérapie cellulaire MEA CAR-T 

Le paysage concurrentiel du marché du traitement par thérapie cellulaire MEA CAR-T fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de vie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.  

Certains des principaux acteurs du marché opérant sur le marché sont Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company et Johnson & Johnson Services, Inc., entre autres.  

SKU-61531